Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.51 |
| ▸ | HTR1B | P28222 | 4/20 | 0.51 |
| ▸ | HTR1A | P08908 | 12/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR1E | P28566 | 1/20 | 0.44 |
| ▸ | HTR1F | P30939 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.44 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9263047 | 0.99 | HTR1D (0.50) | HTR1DHTR1BHTR1AHTR2AHTR7 | |
| SCHEMBL4353972 | 0.92 | HTR1A (0.43) | HTR1DHTR1BHTR1AHTR7SLC6A4 | |
| SCHEMBL4558261 | 0.91 | HTR1A (0.42) | HTR1DHTR1BHTR1AHTR2AHTR7 | |
| SCHEMBL4350474 | 0.89 | HTR1A (0.42) | HTR1DHTR1BHTR1AHTR2AHTR7 | |
| SCHEMBL4352038 | 0.89 | HTR1A (0.43) | HTR1DHTR1BHTR1AHTR7SLC6A4 | |
| Avitriptan SCHEMBL147315 | 0.88 | HTR1D (0.55) | HTR1DHTR1BHTR1AHTR2AHTR7 | |
| Avitriptan SCHEMBL29633456 | 0.88 | HTR1D (0.55) | HTR1DHTR1BHTR1AHTR2AHTR7 | |
| Avitriptan SCHEMBL4352074 | 0.88 | HTR1D (0.54) | HTR1DHTR1BHTR1AHTR2AHTR7 | |
| SCHEMBL4347875 | 0.86 | HTR1A (0.42) | HTR1AHTR7SLC6A4KCNH2 | |
| SCHEMBL6356507 | 0.86 | USP2 (0.43) | HTR1DHTR1AHTR7SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | claimed |
| US-20050095286-A1 | Extended release compositions | FABRE KRAMER PHARMACEUTICALS, INC. (US) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050095286-A1 | Extended release compositions | PDE3A, GIPR, PDE7A | HTR1D 29/4885HTR1B 38/4885HTR1A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.